InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,402.40
(
0.00%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.56
(
-0.41%
)
Bitcoin
65,637.17
(
-1.28%
)
Post# of 252233
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: biomaven0 post# 147962

Thursday, 08/30/2012 2:14:03 PM

Thursday, August 30, 2012 2:14:03 PM

Post# of 252233
On "solanezumab is not dead yet" issue

Agree on both your points - there is a small signal, probably not clinically significant but could be disease modifying.
I'm thinking: if the effect correlates with the biomarkers, it would be worth trying another trial perhaps in prodromal AD patients and negotiate with the FDA on using these biomarkers along with cognitive measure as efficacy endpoints.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up